Fatal brake failures: Tumorigenesis in the colon

by Ludwig Maximilian University of MunichMir34a/p53-deficient metastatic colon cancer cells invading into a lymph node. Brown staining detects high levels of nuclear beta-catenin protein, which i

Updated on: March 08,2024

Fatal brake failures: Tumorigenesis in the colon

by Ludwig Maximilian University of MunichMir34a/p53-deficient metastatic colon cancer cells invading into a lymph node. Brown staining detects high levels of nuclear beta-catenin protein, which i

Updated on:March 08,2024

New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds

byUniversity of MichiganCredit: Ivan Samkov from PexelsAs prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for m

Updated on: September 28,2024

New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds

byUniversity of MichiganCredit: Ivan Samkov from PexelsAs prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for m

Updated on:September 28,2024

First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral cris

Updated on: February 01,2024

First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainIn patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral cris

Updated on:February 01,2024

Researchers suggest rethinking 'cancer' label for early-stage prostate changes

byOxford University PressCredit: CC0 Public DomainA new paper in theJournal of the National Cancer Instituteindicates that patients may benefit if doctors stop calling certain early-

Updated on: November 10,2024

Researchers suggest rethinking 'cancer' label for early-stage prostate changes

byOxford University PressCredit: CC0 Public DomainA new paper in theJournal of the National Cancer Instituteindicates that patients may benefit if doctors stop calling certain early-

Updated on:November 10,2024

Immune targets for chemotherapy-resistant breast cancers identified

byKing's College LondonAnalysis of stromal TILs in residual disease and prognostic implications. A) Kaplan–Meier curves for i) progression free survival and ii) overall survival in ER+HER2-

Updated on: January 02,2024

Immune targets for chemotherapy-resistant breast cancers identified

byKing's College LondonAnalysis of stromal TILs in residual disease and prognostic implications. A) Kaplan–Meier curves for i) progression free survival and ii) overall survival in ER+HER2-

Updated on:January 02,2024

Researchers develop new one-two punch against melanoma in mouse model

by Johns Hopkins University School of MedicineCredit: Kimmel Cancer CenterResearchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University

Updated on: June 04,2024

Researchers develop new one-two punch against melanoma in mouse model

by Johns Hopkins University School of MedicineCredit: Kimmel Cancer CenterResearchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University

Updated on:June 04,2024

New study brings personalized immunotherapy prescriptions a step closer

byUniversity of BathCredit: Unsplash/CC0 Public DomainIn a step likely to advance personalized cancer treatment, scientists have—for the first time—shown in patients that levels of biomarkers ar

Updated on: January 13,2024

New study brings personalized immunotherapy prescriptions a step closer

byUniversity of BathCredit: Unsplash/CC0 Public DomainIn a step likely to advance personalized cancer treatment, scientists have—for the first time—shown in patients that levels of biomarkers ar

Updated on:January 13,2024

Targeting a unique metabolic pathway might starve pancreatic cancer

by Nancy Fliesler and Andrea Tamayo,Broad Institute of MIT and HarvardMItochondrial staining (red) and nuclear staining (blue) of abnormal pancreatic ducts from a mouse model of human pancreatic

Updated on: February 18,2024

Targeting a unique metabolic pathway might starve pancreatic cancer

by Nancy Fliesler and Andrea Tamayo,Broad Institute of MIT and HarvardMItochondrial staining (red) and nuclear staining (blue) of abnormal pancreatic ducts from a mouse model of human pancreatic

Updated on:February 18,2024

Resetting the epigenetic balance for cancer therapy

by Will Doss,Northwestern UniversityKiller T cells surround a cancer cell. Credit: NIHThough mutations in a gene called MLL3 are common across many types of cancers, their relationship to the de

Updated on: April 07,2024

Resetting the epigenetic balance for cancer therapy

by Will Doss,Northwestern UniversityKiller T cells surround a cancer cell. Credit: NIHThough mutations in a gene called MLL3 are common across many types of cancers, their relationship to the de

Updated on:April 07,2024

ASCO: liquid biopsy accurate for detecting colorectal cancer

(HealthDay)—Liquid biopsy that identifies circulating tumor cells in a blood sample has high accuracy for detecting colorectal cancer (CRC), according to a study presented at the American Society of C

Updated on: March 30,2024

ASCO: liquid biopsy accurate for detecting colorectal cancer

(HealthDay)—Liquid biopsy that identifies circulating tumor cells in a blood sample has high accuracy for detecting colorectal cancer (CRC), according to a study presented at the American Society of C

Updated on:March 30,2024

Metachronous pathology assessed in young-onset colorectal cancer survivors

The incidence rate of clinically significant metachronous colorectal pathology is 32 per 1,000 person-years after index young-onset colorectal cancer (YOCRC), according to a research letter published

Updated on: January 02,2024

Metachronous pathology assessed in young-onset colorectal cancer survivors

The incidence rate of clinically significant metachronous colorectal pathology is 32 per 1,000 person-years after index young-onset colorectal cancer (YOCRC), according to a research letter published

Updated on:January 02,2024

Study shows why a common form of immunotherapy fails, and suggests solution

by Georgetown University Medical CenterSamir N. Khleif, MD, director of The Loop Immuno-Oncology Laboratory at Georgetown Lombardi, led the research team that published new research on checkpoint

Updated on: March 01,2024

Study shows why a common form of immunotherapy fails, and suggests solution

by Georgetown University Medical CenterSamir N. Khleif, MD, director of The Loop Immuno-Oncology Laboratory at Georgetown Lombardi, led the research team that published new research on checkpoint

Updated on:March 01,2024